Funding for this research was provided by:
Operational Program “Education and Lifelong Learning” (MIS 376659)
Hellenic Diabetes Association (Κ.Ε. 12008)
Microlife AG, Widnau Switzerland
Received: 8 May 2020
Accepted: 23 October 2020
First Online: 7 November 2020
Ethics approval and consent to participate
: EMENO study was approved by the Ethics and Deontology Committee of the National and Kapodistrian University of Athens (date: November 8, 2012, protocol: 1742) and by the Hellenic Data Protection Authority (date: December 7, 2012, protocol: ΓΝ/ΕΞ/1069–1/07-12-2012). A modified version of the informed consent form (ICF) was approved by the Ethics and Deontology Committee of the National and Kapodistrian University of Athens (date: March 6, 2013, protocol: 6315).
: Not applicable.
: GT has received EU and National resources grants as well as a grant from the Hellenic Diabetes Association, all paid to her institution, to support this study and grants unrelated to this study and paid to her institution from Gilead Sciences Europe, UCL, ECDC, EU, University of Bristol, Harvard University, and National funds; KM and SL have received grants through Hellenic Diabetes Association supporting the current study from Boehringer Ingelheim, Roche, Abbott, MSD and through their Academic center unrelated to this study from Novo Nordisc Hellas, Sanofi Hellas, Astra Zeneca, Novartis, Boehringer Ingelheim, Pharmasery Lilly. GS has received consultations fees and research grants by Microlife AG. The rest of the authors declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.